BruceBBankMD

Oncology • Elk Grove Village, IL

Hematologic Oncology

Northwest Oncology and Hematology

Join to view full profile

Dr. Bank is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Bank's full profile

Already have an account?

Office
800 Biesterfield Rd
Ste 210
Elk Grove Village, IL 60007
Phone+1 847-437-3312

Summary

Dr. Bruce Bank is an oncologist in Elk Grove Village, IL and is affiliated with multiple hospitals in the area, including Advocate Good Shepherd Hospital, AMITA Health Elk Grove Village, Northwest Community Healthcare, and AMITA Health Hoffman Estates. He received his medical degree from New York University Grossman School of Medicine and has been in practice 37 years. He specializes in hematologic oncology and is experienced in breast cancer, hodgkin's lymphoma, hemolytic-uremic syndrome, bronchial cancer, and b-cell chronic lymphooid leukemia. He has 7 publications and over 250 citings.

Education & Training

Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1980 - 1983
New York University School of MedicineClass of 1980

Certifications & Licensure

IL State Medical License 1991 - 2026
NJ State Medical License 1988 - 1993
NY State Medical License 1981 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2011-2013

Clinical Trials

Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Completed
Phase 4
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox. Start of enrollment: 2014 Sep 11
Terminated
Phase 2
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States Start of enrollment: 2017 Jul 19
Completed
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination Start of enrollment: 2015 Dec 01
Recruiting
Roles: Contact
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer Start of enrollment: 2023 Aug 08
Recruiting
Phase 2, Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the P...
Kevin C Flanagan, Jon Earls, Jeffrey Hiken, Rachel L Wellinghoff, Michelle M Ponder
Journal for Immunotherapy of Cancer. 2024-11-03
3 citations
Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.
Kevin C Flanagan, Jon Earls, Ian Schillebeeckx, Jeffrey Hiken, Rachel L Wellinghoff
Journal of Cancer Research and Clinical Oncology. 2023-11-01
17 citations
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
Randy F. Sweis, Sachdev Thomas, Bruce Bank, Paul A. S. Fishkin, Colin Mooney
Cureus. 2016-02-26

Professional Memberships

American Society of Clinical Oncology - ASCO
Member